search
Back to results

CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy (ORL)

Primary Purpose

Tonsillectomy

Status
Recruiting
Phase
Phase 2
Locations
Portugal
Study Type
Interventional
Intervention
Oradexon
Ropivacaine
Saline solution
Sponsored by
Clinical Academic Center (2CA-Braga)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tonsillectomy focused on measuring Tonsillectomy, Pain management

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) physical status I-II;
  • Surgical proposal of tonsillectomy;
  • Tonsillectomy performed by the cold shedding technique;
  • History of recurrent tonsillitis, caseous tonsillitis and / or peritonsillar abscess;

Exclusion Criteria:

  • Use of chronic analgesic medication;
  • ASA III-IV;
  • Coagulation disorders, such as von Willebrand disease or diagnosis of other platelet disorders, haemophilia A and B, or diseases that may develop with hemostatic dysfunction;
  • Intolerance or allergy to any of the drugs used in the study;
  • Suspicious or confirmed diagnosis of neoplastic disease;
  • Fever or acute respiratory tract infection in the last 3 weeks;

Sites / Locations

  • Serviço de Otorrinolaringologia, Hospital de BragaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Experimental

Placebo Comparator

Arm Label

dexamethasone

ropivacain

ropivacain + dexamethasone

placebo

Arm Description

12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total). Single dosage pre-incisional.

18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total). Single dosage pre-incisional.

18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca). Single dosage pre-incisional.

Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.

Outcomes

Primary Outcome Measures

Change in pain assessment using the VAS
Alteration in Visual Analogue Scale values (1-100mm) to assess pain at rest and during swallowing
Time to first administration of analgesia
Time until it is needed to administer analgesia to the patient, after surgery (in minutes)
Paracetamol intake
Number of paracetamol intakes
Paracetamol cumulative dosage intake
Cumulative dosage of paracetamol intake in mg
Rescue analgesia intake
Number of rescue analgesia intakes (tramadol)
Need of Pethidine
Need of pethidine in immediate post-surgery (yes/no)
Time to need of Pethidine
Time until pethidine admnistration is needed, since the end of surgery (minutes)
Time to onset of water intake, liquid and solid oral diet
Time to onset of water intake, liquid and solid oral diet, since the end of surgery (minutes)

Secondary Outcome Measures

Safety outcome
Number of adverse events

Full Information

First Posted
May 26, 2022
Last Updated
August 16, 2022
Sponsor
Clinical Academic Center (2CA-Braga)
search

1. Study Identification

Unique Protocol Identification Number
NCT05504967
Brief Title
CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy
Acronym
ORL
Official Title
Single-center, Double-blind, Placebo-controlled Study Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine and Dexamethasone for Pain Management After Tonsillectomy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 22, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinical Academic Center (2CA-Braga)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, controlled, double-blind clinical trial to evaluate the effect of local infiltration of ropivacaine and dexamethasone, alone or in association, in the reduction of pain and the need for supplementary analgesia, after tonsillectomy, in the immediate and late postoperative period, in individuals aged 18 to 65 years. The present clinical trial will include 4 study groups, each with different content of infiltration into the amygdaline locus. One group will have ropivacaine in the infiltration, the other will have dexamethasone and another the association of these two drugs. In order to better understand the effectiveness of these drugs, there will also be a control group, in which saline solution will be infiltrated. Approximately 104 individuals, aged 18 to 65 years, proposed for tonsillectomy will be included in the study, i.e., 26 subjects in each study group. Postoperative pain will be characterized by self-assessment through the Visual Analog Scale (VAS, 100mm) at various moments of the study, namely in the preoperative consultation, in the pre-anesthetic consultation, at hospital admission and in the postoperative period until the 15th day after the surgery. The aim of this study is not to eliminate intra and postoperative analgesia, but rather account for the need for analgesia depending on the different infiltration content peramygdalin. For this, in the postoperative period, a careful pain monitoring, having first-line analgesic and rescue medication for use immediate response in the face of minimal pain assessed by validated pain scales. It is intended, therefore, to record which analgesic drugs and in what doses were necessary.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tonsillectomy
Keywords
Tonsillectomy, Pain management

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
randomized, controlled, double-blind clinical trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
104 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
dexamethasone
Arm Type
Active Comparator
Arm Description
12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total). Single dosage pre-incisional.
Arm Title
ropivacain
Arm Type
Active Comparator
Arm Description
18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total). Single dosage pre-incisional.
Arm Title
ropivacain + dexamethasone
Arm Type
Experimental
Arm Description
18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca). Single dosage pre-incisional.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.
Intervention Type
Drug
Intervention Name(s)
Oradexon
Other Intervention Name(s)
dexamethasone
Intervention Description
With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Intervention Description
With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Intervention Type
Drug
Intervention Name(s)
Saline solution
Intervention Description
With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Primary Outcome Measure Information:
Title
Change in pain assessment using the VAS
Description
Alteration in Visual Analogue Scale values (1-100mm) to assess pain at rest and during swallowing
Time Frame
Change from baseline (90 days before surgery; day of surgery, day 1, 2, 3, 7 and 15 after surgery)
Title
Time to first administration of analgesia
Description
Time until it is needed to administer analgesia to the patient, after surgery (in minutes)
Time Frame
From the day of surgery to discharge (an average 1 day)
Title
Paracetamol intake
Description
Number of paracetamol intakes
Time Frame
Time since the end of surgery until post-operative visit (15 days after surgery)
Title
Paracetamol cumulative dosage intake
Description
Cumulative dosage of paracetamol intake in mg
Time Frame
Time since the end of surgery until post-operative visit (15 days after surgery)
Title
Rescue analgesia intake
Description
Number of rescue analgesia intakes (tramadol)
Time Frame
Time since the end of surgery until post-operative visit (15 days after surgery)
Title
Need of Pethidine
Description
Need of pethidine in immediate post-surgery (yes/no)
Time Frame
Immediate post-surgery
Title
Time to need of Pethidine
Description
Time until pethidine admnistration is needed, since the end of surgery (minutes)
Time Frame
Time since the end of surgery until post-operative visit (15 days after surgery)
Title
Time to onset of water intake, liquid and solid oral diet
Description
Time to onset of water intake, liquid and solid oral diet, since the end of surgery (minutes)
Time Frame
Time since the end of surgery until post-operative visit (15 days after surgery)
Secondary Outcome Measure Information:
Title
Safety outcome
Description
Number of adverse events
Time Frame
Time since screening until post-operative visit (15 days after surgery)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status I-II; Surgical proposal of tonsillectomy; Tonsillectomy performed by the cold shedding technique; History of recurrent tonsillitis, caseous tonsillitis and / or peritonsillar abscess; Exclusion Criteria: Use of chronic analgesic medication; ASA III-IV; Coagulation disorders, such as von Willebrand disease or diagnosis of other platelet disorders, haemophilia A and B, or diseases that may develop with hemostatic dysfunction; Intolerance or allergy to any of the drugs used in the study; Suspicious or confirmed diagnosis of neoplastic disease; Fever or acute respiratory tract infection in the last 3 weeks;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Monica Goncalves
Phone
+351 253 027 249
Email
cro@ccabraga.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ana Menezes
Organizational Affiliation
Serviço de Otorrinolaringologia, Hospital de Braga, EPE
Official's Role
Principal Investigator
Facility Information:
Facility Name
Serviço de Otorrinolaringologia, Hospital de Braga
City
Braga
ZIP/Postal Code
4710-243
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rosana Magalhaes
Phone
00351 253 027249

12. IPD Sharing Statement

Learn more about this trial

CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy

We'll reach out to this number within 24 hrs